The decision came right after the US regulator also cleared Bristol-Myers Squibb and 2seventy bio’s rival CAR-T Abecma as a third-line therapy for relapsed or refractory multiple myeloma ...

Bristol Myers Squibb BMY announced that it has obtained FDA approval for the label expansion of Opdivo (nivolumab) plus ...

Bristol Myers Squibb has moved to take full control of the CAR-T therapy it partners with 2seventy bio, agreeing to buy the biotech for around $286m.

With data as of April 9, 2025, we examine if Bristol-Myers Squibb Company(BMY) is consistently building momentum based on ...

Bristol Myers Squibb won the dismissal of a proposed class action accusing it of fraudulently obtaining patents and filing ...

Bristol Myers Squibb (BMY) wins dismissal of a lawsuit filled by Blue Cross Blue Shield of Louisiana alleging antitrust trust ...

Bristol-Myers Squibb Co. got dismissal of a lawsuit alleging the company used reverse-payment agreements to delay the generic ...

The FDA has approved Opdivo plus Yervoy for the first-line treatment of MSI-H/dMMR colorectal cancer, supported by the Phase ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), with a ...